Not available
Quote | CymaBay Therapeutics Inc. (NASDAQ:CBAY)
Last: | $14.68 |
---|---|
Change Percent: | 0.6% |
Open: | $14.82 |
Close: | $14.68 |
High: | $15.18 |
Low: | $14.53 |
Volume: | 1,364,255 |
Last Trade Date Time: | 10/02/2023 03:00:00 am |
News | CymaBay Therapeutics Inc. (NASDAQ:CBAY)
2023-09-26 16:29:38 ET More on Intercept Pharma Seeking Alpha’s Quant Rating on Intercept Pharma Intercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Parties Intercept: Narrowed Market, Concentrated Strategy (Rating Upgrade) ...
2023-09-21 16:39:43 ET Shares of CymaBay Therapeutics (NASDAQ: CBAY) were sinking 11.3% lower this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence . The decline extended a sell-off that began last week following the b...
Message Board Posts | CymaBay Therapeutics Inc. (NASDAQ:CBAY)
Subject | By | Source | When |
---|---|---|---|
MomentumIts gaining up | jerseyboy | investorshub | 06/29/2023 10:29:09 PM |
great news | oilin07 | investorshub | 06/27/2023 5:22:29 PM |
what do you make of this data? | TonyJoe1957 | investorshub | 06/27/2023 12:33:09 AM |
Anyone hear anything lately? Want to see this one go | swingingRichard | investorshub | 06/24/2023 5:09:53 PM |
$CBAY The trading last trade up | swingingRichard | investorshub | 06/22/2023 2:55:50 PM |
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar...
2023-09-21 16:39:43 ET Shares of CymaBay Therapeutics (NASDAQ: CBAY) were sinking 11.3% lower this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence . The decline extended a sell-off that began last week following the b...
AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to support post-marketing regulatory requirements for seladelpar’s accelerated approval pathway NEWARK, Calif., Sept. 21, 2023 (GLOBE NEWSWIR...